Clarus Therapeutics (CRXT) Stock Analysis

What Clarus Therapeutics does

Clarus Therapeutics Holdings, Inc., an Illinois-based pharmaceutical enterprise established in 2003, primarily concentrates on the creation and commercialization of oral testosterone replacement therapies across the United States. Its key offering, JATENZO, is a soft gel oral formulation of testosterone undecanoate designed for managing hypogonadism in men. The company also maintains strategic licensing agreements: one with HavaH Therapeutics for androgenic treatments aimed at inflammatory breast disease and specific forms of breast cancer, and another with The Royal Institution for the Advancement of Learning/McGill University to advance proprietary technology for addressing CoQ10 deficiencies.

Key metrics

ETFs linked to CRXT

Broad-market and Healthcare sector ETFs an investor holding Clarus Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CRXT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Clarus Therapeutics?

Clarus Therapeutics trades under the ticker CRXT on NASDAQ.

Which exchange is CRXT listed on?

CRXT is listed on NASDAQ.

What sector does Clarus Therapeutics operate in?

Clarus Therapeutics is classified in the Healthcare sector (Drug Manufacturers - General industry).

How can PortView help analyze CRXT in a portfolio?

PortView shows CRXT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.